ロード中...
NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response
Novel adjuvants are needed to increase the efficacy of vaccine formulations and immune therapies for cancer and chronic infections. In particular, adjuvants that promote a strong type I IFN response are required, since this cytokine is crucial for the development of efficient anti-tumoral and anti-v...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5814164/ https://ncbi.nlm.nih.gov/pubmed/29464024 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23725 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|